期刊文献+

海藻酸钠在药物制剂中的研究进展 被引量:27

Pharmaceutical significance of sodium alginate
下载PDF
导出
摘要 海藻酸钠是从海带或海藻中提取的天然多糖类化合物,作为缓释制剂辅料广泛应用于片剂、微丸、微囊、脂质体、纳米粒等缓释制剂中,现综述近年来海藻酸钠作为辅料的影响因素及在缓释制剂中的应用研究进展。 Alginate is a natural polysaccharide polymer isolated from seaweeds or algae, which is widely used as a sustained-release excipient of tablets, pellets, microspheres, liposome and nanoparti- cles. This paper reviews key elements that make sodium alginate used as excipients as well as recent pro- gresses of sodium alginate used in sustained-release formulation.
出处 《中国新药杂志》 CAS CSCD 北大核心 2007年第8期591-594,共4页 Chinese Journal of New Drugs
关键词 海藻酸钠 缓释制剂 辅料 alginate sodium sustained-release formulation excipient
  • 相关文献

参考文献27

  • 1王康,何志敏.海藻酸微胶囊的制备及在药物控释中的研究进展[J].化学工程,2002,30(1):48-54. 被引量:40
  • 2TONNESEN HH,KARLSEN J. Alginate in drug delivery systems [J]. Drug Dev Ind Pharm, 2002,28(6) :621 -630.
  • 3罗明生.药剂辅料大全[M].四川:科学技术出版社,1992.156.
  • 4蒋新国,王孝俊,朱芳海,李正伟,奚念朱.海藻酸钠的分子量与缓释作用[J].药学学报,1994,29(4):306-310. 被引量:18
  • 5马萍,孙淑英,刘东春,王文俭.海藻酸钠理化参数的测定[J].中国海洋药物,2000,19(3):54-56. 被引量:19
  • 6AKIHIKO K, MINAKO K, ATSUSHI W, et al. Effect of Ca^2+ - alginate gel dissolution on release of dextran with different molecular weights [ J ]. J Controlled Release, 1999,58 ( 1 ) :21 - 28.
  • 7蒋新国,何继红,奚念朱.海藻酸钠和脱乙酰壳多糖混合骨架片剂的缓释特性研究[J].中国药学杂志,1994,29(10):610-612. 被引量:15
  • 8PEPPERMAN AB, KUAN JCW. Alginate controlled release formulation of melrivuzin[ J]. J Controlled Release, 1991,19 ( 1 ) : 105 -111.
  • 9NOKHODCHI A, TAILOR A. In situ cross-linking of sodium alginate with calcium and aluminum ions to sustain the release of theophylline from polymeric matrices [ J ]. Farmaco, 2004,59 ( 8 ) :999 - 1004.
  • 10TAPIA C,ESCOBAR Z, COSTA E, et al. Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem clorhydrate release systems[J]. Eur J Pharm Biopharm, 2004,57( 1 ) :65 -75.

二级参考文献55

  • 1董志超,蒋雪涛.羟丙基甲基纤维素在凝胶骨架片的应用[J].国外医药(合成药.生化药.制剂分册),1993,14(1):41-44. 被引量:31
  • 2陆兵,石庭森.酸性染料法测定盐酸平痛新含量[J].药物分析杂志,1995,15(1):54-56. 被引量:4
  • 3周廷冲.实用药学辞典[M].天津:天津科学技术出版社,1991.26-27.
  • 4刘秀洞.膜乳化法制备壳聚糖/海藻酸微胶囊.第九届全国生物化工学术会议论文集[M].-,2000.475-477.
  • 5Cohen S, Lobel E, Trevgoda A, et al. A novel in situ-forming ophthalmic drug delivery systems from alginates undergoing gelation in the eye [J] .J Controlled Release, 1997,44(2-3) :201.
  • 6Gurny R, Boye T, lbrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery [J ]. J Controlled Release, 1985,2(3 ): 353.
  • 7Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system [ J ]. J Controlled Release ,2001,73(2) :205.
  • 8Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J ]. J Controlled Release ,2000,69(3 ) :379.
  • 9Yun MO,Choi HG,Jung JH,et al. Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement [J]. Int J Pharm, 1999,189(2) : 137.
  • 10Desai SD,Blanchard J. Evaluation of Pluronic F127 sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model [J ]. J Pharm Sci, 1998,87(10) : 1190.

共引文献221

同被引文献342

引证文献27

二级引证文献152

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部